1. Scrip

Shire Tempts Busch From Bayer As It Eyes Top Spot In Rare Diseases

 
• By Kevin Grogan

The appointment of Andreas Busch as its new head of R&D represents a boost for Shire which has 17 programs in late-stage development, headed by the potential HAE blockbuster SHP643.

Keys
Shire hands over the keys to the R&D cupboard to Bayer's Andreas Busch • Source: Shutterstock

Having poached Andreas Busch from Bayer AG to be his R&D chief days after appointing a new finance head, Shire PLC CEO Flemming Ornskov has now put together a strong management team to push the company towards its goal of becoming the leading player in the rare diseases space.

The news that Busch has jumped ship from Bayer, where he was in charge of drug discovery, to become Shire's head of R&D and chief scientific officer in January caused quite a stir not least because the announcement came on the day (Dec. 1) when the German group held a high-profile press meeting to present its own research strategy. It was particularly surprising given that Busch was scheduled to speak at the event in Berlin

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Rare Diseases

More from Scrip

In Brief: Genmab To Seek FDA Nod For Epkinly In Lymphoma

 
• By Sushmita Panda

Genmab will submit an sBLA for Epkinly in R/R follicular lymphoma in H1 2025, backed by positive Phase III data.

Pharma Predicts Modest Impact From Tariffs, But It Depends On What Comes Next

 
• By Jessica Merrill

Drugmakers aren’t expecting a big financial hit from tariffs for now, but a report commissioned by PhRMA suggests the cost of pharma-sector tariffs could be steep.

OPPI’s Matai On Section 3(d) Of India’s Patent Regulations: Now’s The Time To Open Up

 
• By Anju Ghangurde

Anil Matai, director general, Organization of Pharmaceutical Producers of India, talks in this audio interview about the evolving intellectual property landscape in India post the 2024 amendments, including long-standing sticking points such as Section 3(d) of India’s patent regulations and innovator firms' experience of the Bolar provision. There’s also a "compelling reason" to consider regulatory data protection, he claims.